AuraSonics is building a category-defining, defensible architecture in non-invasive cardiac sensing: a high-density, dual-energy, AI-readable thoracic signal platform protected by a layered patent portfolio. We are raising a seed round to convert the provisional portfolio into utility patent applications and a first working prototype — and the first dollar doesn't disappear into burn. It goes straight to one of the world's top life-sciences law firms to advance the IP.
We are defining a new category — Wearable Cardiac Tomography. This is the entry point: the moment before the category is priced in, when early conviction is rewarded with the simplest terms it will ever have.
Cardiovascular disease is the world's leading cause of death. Today's cardiac diagnostics are powerful, but many definitive pathways are episodic, resource-intensive, and triggered only after symptoms, referral, or clinical suspicion. Capital is flowing into AI-enabled, non-invasive sensing — and the best-funded names are chasing a far narrower signal than ours.
And this moat compounds. A single-point device can record a million patients and never hold what a coordinate-aligned field captures in one session. The competitor who starts five years late starts five years of irreplaceable data behind — a lead that capital alone cannot buy back.
Cardiovascular disease remains the world's leading cause of death — an estimated 19.8 million deaths in 2022 — and far too often found only after the crisis.
Eko alone has raised over $150M — to connect one acoustic sensor to AI. The field is hot; the incumbents are technically narrow — and a sensor on the chest moves with the chest, so it can't read the heart's motion at all.
Medtech venture funding rebounded through 2025 and AI-enabled healthtech is in strong demand — an ideal backdrop for a seed.
Independent analysts size the global cardiovascular-diagnostics market in the low-to-mid tens of billions today, growing at a high-single-digit rate as care shifts from episodic testing toward continuous, AI-enabled, non-invasive sensing. AuraSonics is built for exactly that shift — and aims to define a category inside it rather than fight for a sliver of the old one.
Multiple independent analyst groups value the global cardiovascular-diagnostics market in the low-to-mid tens of billions of dollars, expanding at a high-single-digit CAGR.
Forecasts put the market past $25B by the mid-2030s — pulled by AI, wearables, and remote monitoring, the precise tailwinds AuraSonics is designed to ride.
By design, AuraSonics has no direct analogue today: no competitor captures both acoustic and mechanical energy across a 3,000-point, coordinate-aligned field. The category it is defining is, so far, its own.
Market figures are third-party analyst estimates, cited as a range and rounded; they describe the opportunity, not a projection of AuraSonics revenue.
Most pre-seed money funds runway and hope. Ours funds a specific, verifiable asset. An angel's contribution can be ring-fenced and paid directly to Wilson Sonsini to convert our five provisional filings into utility patents — the single step that most increases this company's value.
Angel / advisor contribution
Not to burn. Not to salaries. Earmarked for the IP.
Provisional → utility, by top counsel
Wilson Sonsini has supported AuraSonics' formation and IP foundation, giving investors a clean corporate and legal starting point.
$0 raised, single founder-director, company formed by WSGR. You enter early, on simple terms.
Utility filings authored by world-renowned counsel carry weight that opens the doors a founder cannot open alone.
The instrument is open to discussion — SAFE or priced. The entry point is yours to choose.
A focused, earmarked contribution paid directly to counsel to file the utility patents. The cleanest possible first step into the company.
The full round to carry AuraSonics from protected IP to a working belt and first human feasibility data — on the path toward an FDA regulatory strategy.
AuraSonics is raising $1.0–1.5M to complete the provisional-to-utility patent conversion, build the first working sensing belt, validate bench signals, and prepare the first human feasibility recordings.
An initial ring-fenced patent-conversion tranche may be paid directly to Wilson Sonsini, subject to investor agreement and counsel coordination.
IP first — because the patent conversion is the highest-leverage, lowest-risk value creation available to this company today.
Allocation is representative and will be finalized with lead investors. Belt fabrication partners in Malaysia and South Korea have already been identified against existing specifications.
Provisional → utility conversion completed by Wilson Sonsini.
First working belt built to existing specifications, with bench signal validation.
Initial feasibility recordings and a physician-facing dashboard mockup.
Regulatory pathway memo, pilot-site letters of intent, and an initial dataset for model development.
We believe in showing the team honestly. The technical foundation is in place; this round funds the credibility and the advisors that come next.
Inventor of the AuraSonics architecture. Background in physics and electronics / communications engineering. Full-time, founder-funded, U.S.-based.
A practicing cardiologist to guide indication and validation design.
In formationTo shape the FDA pathway (510(k) / De Novo) and pre-submission strategy.
In formationMultimodal acquisition, denoising, and feature extraction.
In formationSoft-materials fabrication and belt manufacturing.
In formationModel architecture, validation, and clinical ML governance.
In formationOne of the world's leading technology and life-sciences law firms. Engaged on formation and IP; available to speak with serious prospective investors about the patent portfolio.
Funding the utility filings is not the end of the story. It is the key that starts the sequence.
WSGR-authored, examiner-ready, defensible claims.
Top-firm-backed IP that founders can't replicate alone.
Top-tier counsel and a clean foundation give investors confidence and accelerate diligence.
Aligned cardiology-focused capital — at a stronger position.
Belt fabrication and first feasibility data begin.
No spin. The honest version of every answer — because the diligence will find it anyway.
The conversion of the provisional portfolio into utility patent applications, the first working sensing belt, and initial bench validation. The entry tranche can be ring-fenced and paid directly to Wilson Sonsini — your dollar becomes a defensible asset, not runway.
Eko and the "smart stethoscope" field digitize and amplify a single acoustic point. AuraSonics captures two physically different energies — acoustic and mechanical — across 3,000 coordinate-aligned points. A sensor that moves with the chest physically cannot read the motion we resolve. A different sense, not a better microphone.
No — and we say so plainly. AuraSonics is development-stage; figures such as >70 dB SNR and 1–3 mm localization are engineering and modeled targets, not clinical results. This round funds the first steps toward validating them. Honest framing today is what survives diligence tomorrow.
A layered, interlocking architecture spanning the sensing hardware, the AI diagnostic pipeline, and the multimodal data-fusion engine — anchored by one filed nonprovisional utility application (CARD-001) and four active provisional applications (CARD-002 through CARD-005) now entering the utility-conversion stage. And a data moat that compounds: a coordinate-aligned field cannot be reconstructed after the fact by a rival who starts late.
Open to discussion — SAFE or priced — and intentionally simple at this stage. Begin with the ring-fenced patent-conversion tranche, or back the full $1.0–1.5M seed. You may speak directly with our counsel before committing a single dollar.
Capital is flowing into AI-enabled, non-invasive cardiac sensing; the market is scaling past $25B; and the category is still unpriced. This is the entry point — when early conviction is rewarded with the simplest terms it will ever have.
This page is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security. Any such offer will be made only to qualified investors pursuant to definitive offering documents. Statements about future plans, milestones, and markets are forward-looking and subject to risk and uncertainty. AuraSonics, Inc. is a development-stage company; its technology is the subject of pending provisional patent applications, has not been clinically validated, and is not FDA-cleared. Performance figures referenced elsewhere on this site are engineering or modeled targets.